Apoptosis-inducing agents: A patent review (2010-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 3, 2014, Pages 339-354

  Kamal, Ahmed ^a   Faazil, Shaikh ^a   Malik, Mohammed Shaheer ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Apoptosis; Apoptosis inducers; Bcl 2 proteins; Cancer drug development; Caspases; Heterocyclics; Sulfonamides

Indexed keywords

AMIDE; AMINO ACID TRANSPORTER; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; BH3 PROTEIN; BI 97C1; CANCER VACCINE; CARBON NANOTUBE; CHALCONE DERIVATIVE; GOSSYPOL; HETEROCYCLIC COMPOUND; INDOLIZINE DERIVATIVE; ISOSORBIDE; ISOXAZOLINE DERIVATIVE; MONOCLONAL ANTIBODY; NATURAL PRODUCT; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PEPTIDE DERIVATIVE; PROBIOTIC AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN NOXA; QUINAZOLINONE DERIVATIVE; SABUTOCLAX; STEVIOL; SULFONAMIDE; THYMOQUINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CYTOPLASM; DNA BINDING; DNA FRAGMENTATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MAMMAL CELL; MICROTUBULE ASSEMBLY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NERVE FIBER GROWTH; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; NEOPLASMS; PATENTS AS TOPIC; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896698045     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.877445     Document Type: Review

References (101)

1. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012;19:107-20.. In-depth discussions related to pathways involved and types of apoptosis.
2. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-98
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57
4. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000;407:796-801
5. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002;109:97-107
6. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21
7. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6
8. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;2:8543-67
9. Gastman BR. Apoptosis and its clinical impact. Head Neck 2001;23:409-25
10. Chipuk JE, Green DR. How do Bcl-2 proteins induce mitochondrial outer membrane permeabilization Trends Cell Biol 2008;18:157-64
11. Thornberry NA. Caspases: Key mediators of apoptosis. Chem Biol 1998;5:R97103
12. Available from: Http://www.britannica. com/EBchecked/topic/264227/ heterocyclic-compound/277878/Five-andsix-membered-rings-with-two-or- moreheteroatoms
13. Aberra F. Roll of pharmacologically active metabolites in drug discovery and development. Drug Discov Today 2006;11:133-42
14. Kunzer AR, Elmore SW, Hexamer A, et al. Preparation of heterocyclic apoptosis-inducing agents for treatment of cancer and immune disorders. WO083442; 2010
15. Wang Z. Preparation of heteroarylmethylenepyrrole derivatives for use as apoptosis inducers. WO053045; 2013. Authors describe active novel compounds which inhibit the antiapoptotic protein Bcl-2 family.
16. Ham SU. Preparation of 2-aminothiazole derivatives as antitumor agents. KR017196; 2012
17. Lee YH, Shin SY, Lim YH, et al. Preparation of bis(2-hydroxylbenzylamino) (pyridin-2-yl) methane as apoptosis inducer. KR139392; 2011
18. Bae IH, Jun MA, Song JY, et al. Preparation of pyrazinone derivatives having apoptosis-inducing activity. WO090316; 2011
19. Kamal A, Srikanth YVV, Khan MNA, et al. Benzothiazole derivatives as potential anticancer agents and apoptosis inducers and process for the preparation thereof. WO111016; 2012. Authors disclosed the apoptosis induction by modulating PARP and mitochondrial activities.
20. Hergenrother PJ, Peterson QP, Hsu DC, et al. Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs. WO091382; 2010
21. Surolia A, Rai A, Panda D. Rhodanine compounds as tubulin binding anticancer agent and their application in treating cancers. IN2011DE01167; 2012
22. Ikeda T, Ono M, Ueno S, et al. Preparation of 2-azolylpyrrole compounds as tubulin polymerization inhibitors and antitumor agents. WO111831; 2013
23. Hitchcock M, Mengel A, Richter A, et al. Preparation of substituted benzylpyrazoles. WO092512; 2013
24. Lim YH, Lee YH, Ko DS, et al. Preparation of trimethoxyphenyl-4,5- dihydro-1H-pyrazol-3-yl-naphthalen-2-ol derivatives having apoptosis-inducing activity. KR049011; 2012
25. Li N, Cao X, Qiu J. {3-[2-(2-Hydroxy-5-nitrophenyl)-5-phenyl-1-H- imidazole-4-yl]phenyl} phenyl ketone as human PEBP4-targeting antitumor compound, its formulation and application. CN101810608; 2010
26. Kovach JS, Zhuang Z, Lu J. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase. WO014141; 2010
27. Wang L, Doherty G, Wang X, et al. Preparation of substituted benzothiazoles as apoptosis-inducing agents for the treatment of cancer, immune and autoimmune diseases. WO055895; 2013
28. Weinberg JB, Friedman DR, Cianciolo GJ, et al. Method of inducing apoptosis/cell death in leukemia cell using a purine nucleoside analogue. US0319360; 2011. Author described apoptosis inducing property of purine nucleotide in leukemia cell.
29. Le DT, Casara P, Starck JB, et al. New indolizine derivatives, their preparation as pro-apoptotic and antitumor agents and their pharmaceutical compositions containing them. FR2986002; 2013
30. Brown D, Husband AJ, Mor G, et al. Methods using chroman compounds for inducing programmed cell death. CA2641541; 2010
31. Husband AJ, Brown D, Morn G, et al. Methods using chroman compounds for inducing programmed cell death. WO045674; 2010
32. Govindan SV, Goldenberg DM. Camptothecin conjugates with anti-CD22 antibodies for the treatment of B cell diseases. US0305631; 2011
33. Lu X, Zheng Z, Ma Y, et al. Xanthone compounds with antitumor activity, preparation and application thereof. CN101723952; 2010
34. Anderson MB, Willardsen JA, Weiner WS, et al. Preparation of 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis. US0069383; 2010
35. Yanagawa H, Hayakawa I, Shiheido H, et al. Antitumor agent containing thalidomide derivative as active ingredient. WO061862; 2010
36. Cai SX, Vaillancourt MT, Claassen G. Compounds and methods of inducing apoptosis via interaction with chaperonin CCT, use for the treatment of diseases responsive to induction of the caspase cascade, and screening methods. WO008558; 2010
37. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12:104-7
38. Vennemann MB, Thomas MT, Hoelder SB, et al. Preparation of fused pyrimidines as Akt inhibitors. WO091824; 2010
39. Reddy EP, Reddy MVT. Preparation of substituted pyrido[2,3-d]pyrimidin-7 (8H)-ones as lk2 kinase inhibitors and anti-tumor agents. WO075616; 2011
40. Tanuma S, Fujiwara M. Glyoxalase I inhibitors as antitumor agents. JP2011219384; 2011
41. Zhang S, Gao Z, Cheng X, et al. Application of adenosine in preparing antitumor agent. CN102178689; 2011
42. Huang HS, Cha TC, Cha TL. Methods for inhibiting cancer cell proliferation and inducing cancer cell apoptosis using anthraquinone derivative, anthra[2,1-c] [1,2,5]thiadiazole-6,11-dione (NSC745885). US0122937; 2012
43. Cotter FE. Preparation of isoquinolines and pyridopyrimidines for inducing cellular apoptosis. WO125343; 2010. Author described the apoptosis inducing properties of isoquinolines and pyridopyrimidines and pharmaceutically acceptable salts.
44. Pechan P, Havlicek L. 5,7-Disubstituted 3-isopropylpyrazolo[4,3-d] pyrimidines, and their preparation and use for inhibiting proliferation and inducing apoptosis in mammalian cells, specifically in preventing, inhibiting or treating restenosis. WO139288; 2010
45. Kaminishi H, Kinjo J, Tsuchihashi R, et al. 3-(Aminocarbonyl)-1-[5-O-[[1- (6-amino-9H-purin-9-yl)-1-deoxy-beta-Dribofuranos-5-Oyl]phosphonyloxy (oxylato)phosphinyl]-beta-Lribofuranosyl] pyridinium, its preparation, and axon elongation and neurite outgrowth promoter, antitumor agent, and food containing it. WO004917; 2012
46. Adra CN, Aldhfyan A. Use of thiazolobenzimidazole compounds for the treatment of tumors and proliferative disorders. WO077295; 2010
47. Casara P, Le Diguarher T, Durand D, et al. New tricyclic derivatives, their preparation as pro-apoptotic and antitumor agents and their pharmaceutical compositions containing them. WO007248; 2010
48. Bruncko M, Ding H, Doherty G, et al. Preparation of N-(phenylsulfonyl) benzamides and N-(3-pyridylsulfonyl) benzamides as apoptosis-inducing agents for the treatment of cancer and immune diseases and autoimmune diseases. WO138588; 2010
49. Bruncko M, Ding H, Doherty GA, et al. Preparation of N-acylsulfonamide Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases. US0298321; 2010
50. Bruncko M, Dai Y, Ding H, et al. Benzamide-sulfonamide derivatives as apoptosis-inducing agents and their preparation, pharmaceutical compositions and use in the treatment of cancer and immune and autoimmune diseases. US0298323; 2010
51. Hexamer L, Ding H, Elmore SW, et al. Preparation of cyclic sulfonamide compounds as apoptosis-inducing agents that act by inhibiting Bcl-2 proteins for the treatment of cancer and immune and autoimmune diseases. WO083441; 2010
52. Lawrence H, Ge Y, Sebti SM, et al. Preparation of 2-amino-1,4- naphthoquinones and N-aryl-aromatic sulfonamides as proteasome inhibitors for selectively inducing apoptosis in cancer cells. WO005534; 2010
53. Catron ND, Chen S, Gong Y, et al. Preparation of chlorophenyldimethyl cyclohexenylmethylpiperaziny lnitrotetrahydropyranylmethyl aminophenylsulfonylpyrrolo pyridinyloxybenzamide salts and crystalline forms for use as apoptosisinducing agents. WO071336; 2012
54. Birtalan E, Hoelig P, Lindley DJ, et al. Melt-extruded solid dispersions containing an apoptosis-inducing agent. US0108590; 2012
55. Tao ZF, Wang X, Souers AJ, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. WO150016; 2011
56. Yeaman MR, Yount NY. Peptides and methods for inducing programmed cell death and their use as antimicrobial, antitumor, antiinflammatory, and antiproliferative agents. WO103567; 2011
57. Kim TH. An apoptosis-inducing peptide of Noxa protein and its use in cancer therapy. WO027980; 2011
58. Bae IH, Jun MA, Song JY, et al. Preparation of imidazopyrazinone peptide derivatives with apoptosis inducing activity on cells. WO090317; 2011. Explained apoptosis inducing property by targeting IAPs.
59. Condon SM, Deng Y, Laporte MG, et al. Preparation of dimeric Smac peptidomimetics for treating proliferative diseases, particularly cancers and autoimmune diseases. US0003877; 2011
60. Wang S, Sun H. Preparation of diazo bicyclic conformationally constrained Smac peptide mimetics as inhibitors of IAP proteins and inducers of apoptosis. WO050068; 2011
61. Bae IH, Byun EY, Ju HK, et al. Preparation of quinoline or quinazoline peptide derivatives with apoptosis inducing activity on cells. WO030160; 2012
62. Schmidt WI, Messmer D. Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides. WO114539; 2010
63. Park GS, Cha Y. Pharmaceutical composition comprising Tcea3 protein and screening method of candidate materials inhibiting metastasis or inducing apoptosis of cancer cells using the same. KR122925; 2011
64. Zipkin RE, Adams JK, Spiegel S, et al. Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same. US0035959; 2010
65. Salsbury FR, Scarpinato KD, King SB. Chemotherapeutic for inducing an MSH2-dependent apoptotic pathway. US0239522; 2010
66. Ahn JS, Kim BY, He L, et al. Acylamides inducing apoptosis of cancer cells. WO064745; 2010
67. Gao XM, Yu TL, Kathy Q, et al. Hela-cell apoptosis inducing natural compounds from Garcinia paucinervis and therapeutic uses thereof. US0301236; 2011
68. Wu YC, Lu MC, Chang FR, et al. Method of preparation of ethanol extract of Antrodia camphorata for inducing apoptosis. US0210869; 2010
69. Moreno O. Isoflavonoid compositions and methods for the treatment of cancer. WO061413; 2012
70. Kawai J, Simizu T. Apoptosis inducer containing ergosterol derivative for treatment of lung, tongue, or cervical cancer, and production thereof from agaricus. WO073085; 2013
71. Young MP, Mckeown P. Dexanabinol and derivatives thereof for inducing cancer cell apoptosis. WO030106; 2011
72. Kachlany SC. Combination therapy with leukotoxin to treat cancer. WO125942; 2012
73. Yu DS, Liying FB, Wang Y. Flavonoid glycoside of Camellia chrysantha, and preparation method and application thereof. CN102617672; 2012
74. Zhang L, Yu H, Bao J, et al. Application of curcumin in preparing antitumor agent for treating thyroid cancer. CN102319234; 2012
75. Zhang G, Wang Z, Wu J. Application of houttuynoid b in the medicine for treating leukemia. CN102861060; 2013
76. Fu J, Yang L, Qiu Y, et al. Application of celastrol in antitumor agent for treating glioma and preparation method thereof. CN102349917; 2012
77. Zhang Z, Xie F. (E, E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile and its derivatives as Bcl-2 family protein inhibitors for inducing cancer cell apoptosis. CN102212613; 2011
78. Sarkar FH, Mohammad RM. Thymoquinone analogs for the treatment of pancreatic cancer. WO126544; 2011
79. Lim YH, Lee YH, Ko DS, et al. Preparation of chalcone derivative having apoptosis-inducing activity. KR047503; 2012
80. Ukiya M. Antitumor steviol derivatives, and pharmaceuticals and apoptosis inducers containing the derivatives. JP074065; 2011
81. Sebti SM, Hamilton AD, Sill K, et al. Compounds and methods for inducing apoptosis in cancer cells using a bh3 alpha-helical mimetic. WO097133; 2012.. Disclosed a biomimetic approach to apoptosis induction by binding to Bcl-2 protein family.
82. Kamal A, Suresh P, Kumar BA, et al. Synthesis of new 4-beta- acrylamidopodophyllotoxin congeners as antitumour antibiotics and the process for preparation thereof. US0225672; 2013
83. Kamal A, Suresh P, Kumar BA, et al. Biological evaluation of 4-aza-2,3-didehydropodophyllotoxin analogues possessing potent antitumour activity. US522219; 2013
84. Kamal A, Shetti RVCRNC, Reddy KS, et al. Carbazole linked pyrrolo[2,1-c] [1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof. US0131336; 2013
85. Kamal A, Shetti RVCRNC, Ramaiah MJ, et al. Carbazole-pyrrolo [2,1-c][1,4]benzodiazepine conjugates: Design, synthesis, and biological evaluation. Med Chem Commun 2011;2:780-8
86. Kamal A, Bharathi EV, Ramaiah MJ, et al. Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents. Bioorg Med Chem 2010;18:526-42
87. Kamal A, Bharathi EV, Dudekula D, et al. Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) hybrids as potential anticancer agents and process for the preparation thereof. US0095214; 2012
88. Kamal A, Bharathi EV, Reddy JS, et al. Isoxazole/isoxazoline/ combretastatin linked dihydroquinazolinone hybrids a potential anticancer agents and process for the preparation thereof. WO058417A; 2010
89. Kamal A, Bharathi EV, Reddy JS, et al. Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2, 3-dihydroquinazolinone hybrids as anticancer agents. Eur J Med Chem 2011;46:691-703
90. Kamal A, Ramakrishna G, Raju P, et al. Design, synthesis and biological evaluation of imidazo[1,5-a] pyridine-PBD conjugates as potential DNA-directed alkylating agents. Med Chem Commun 2013;4:697-703
91. Kamal A, Ramakrishna G, Raju P, et al. Pyrrolo[2,1-c][1,4] benzodiazepine linked imidazo[1,5-a]pyridine conjugates as potential antitumour agents and process for the preparation thereof. US0253034; 2012
92. Kamal A, Reddy MA, Suresh P, et al. Synthesis of chalcone- amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents. Bioorg Med Chem 2012;20:3480-92
93. Kamal A, Reddy MA, Suresh P, et al. Amidobenzothiazole analogues useful as potential anticancer agents and process for the preparation thereof. WO104857A1; 2012
94. Kamal A, Viswanath A, Murty JNSC, et al. Diaryl ether linked pyrrolo[2,1-c] [1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof. WO110840; 2012
95. Gesguiere A, Mathew M, Hu Z. Cancer therapy via selective uptake of specialized polymer/fullerene nanoparticles in cancer cells to induce apoptosis. US0129664; 2013
96. Biris A, Mahmood M. Compositions comprising nanoparticles and apoptotic agents and methods of use as cancer chemotherapeutics. WO129797; 2010
97. Naren M, Chen Z, Liu P, et al. Drug composition for inducing mitochondria apoptosis of multiple myeloma cells. CN103099816; 2013
98. Blander JM, Torchinsky M. Oral or mucosal vaccines comprising microbeinfected apoptotic cell expressing exogenous antigen for inducing TH17 helper cell response against cancer, autoimmune and TH17-associated diseases. WO068680; 2010
99. Nashimoto M. Heptamer-type small guide nucleic acid capable of inducing apoptosis of human hematologic cancer cells. WO022092; 2013
100. Masuko T, Tanba S, Shindo T, et al. Preparation of antibodies specific for LAT1 neutral amino acid transporter and their application as anticancer agents. JP024537; 2011
101. Foo HL. Tumor cytotoxic agent and methods thereof using probiotic lactic acid bacteria that produce metabolites. WO074351; 2012